Introduction {#s1}
============

*In vivo* drug probe phenotyping is the current gold standard approach to evaluate cytochrome P450 (CYP) phenotype in order to account for sources of between- and within- subject variability in metabolic clearance ([@B17]). This approach, which is used extensively in academic and industry research, involves the administration of a drug that is a selective substrate for an enzyme of interest and subsequent collection of timed blood samples, typically over 24--48 h, in order to determine the area under the plasma drug concentration time curve (AUC) ([@B21]). By assessing the probe drug's AUC across different populations (e.g., racial/ethic groups, genotype) or before and after the administration of an interacting drug (e.g., potential enzyme inducer), it is possible to define the impact of an interacting drug or a population characteristic on the phenotype of the target CYP.

In terms of the application, CYP3A4 and 3A5 (collectively referred to as CYP3A) are the most clinically important drug metabolizing enzymes thus the most frequently investigated in phenotyping studies ([@B32]). By way of example, in drug development when a new chemical entity (NCE) is identified in pre-clinical testing as a potential 'perpetrator' of a metabolic drug-drug interaction (DDI) involving CYP3A, a phenotyping study is required to assess the change in AUC for a sensitive CYP3A substrate pre-/post-dosing of the NCE ([@B19]; [@B8]). When evaluating CYP3A phenotype, midazolam is the most commonly used probe and is recommended as such in US Food and Drug Administration (FDA) guidance ([@B6]). Midazolam is an intermediate hepatic clearance (CL~H~ = 27 L/h) drug that is extensively metabolized by CYP3A4, CYP3A5, and CYP3A7 ([@B29]) making it an ideal probe to determine both hepatic and intestinal CYP3A phenotypes when administered orally ([@B24]; [@B25]; [@B26]).

The key challenge that limits the use of phenotyping for CYP3A in academic research settings and preclude the use of this approach in a clinical setting is the logistical burden of collecting blood samples for up to 24--48 h post dose following the administration of a probe drug with or without an interacting drug ([@B18]). In order to circumvent this limitation, several endogenous biomarker based strategies have been proposed to characterize CYP3A phenotype ([@B1]; [@B12]; [@B16]; [@B20]). While these strategies may ultimately replace the need to administer a drug probe, none have been adopted to date due to either inherent biological limitations (e.g., the complexity of steroid metabolism which involves multiple sequential, parallel or alternate metabolic pathways for the substrate (probe) synthesis, substrate metabolism and product metabolism) ([@B30]) or a current limited body of evidence (e.g., extracellular vesicle derived protein, *ex vivo* activity or mRNA biomarkers) ([@B16]). Similarly, several strategies including the administration of midazolam micro-dosing ([@B5]; [@B7]), evaluation of a plasma hydroxy-midazolam to midazolam metabolic ratios ([@B22]; [@B3]), and limited PK sampling strategies ([@B11]; [@B9]; [@B14]; [@B23]; [@B13]; [@B31]) have been proposed, but have not been widely adopted. Of these strategies, to date only the use of a 75 µg oral micro-dose has been rigorously verified ([@B7]). The notable limitation with this micro-dose strategy that continues to limit its application is that it requires access to a sufficiently sensitive analytical platform capable of quantifying femtomolar midazolam concentrations in plasma ([@B2]; [@B7]). Likewise, the use of a single hydroxy-midazolam to midazolam concentration ratio collected at a specific time point as a surrogate for midazolam AUC has largely been discredited as a viable option given the poor concordance of this metabolic ratio with midazolam exposure ([@B11]).

Similarly, the performance of existing limited sampling protocols ([@B10]; [@B11]; [@B9]; [@B14]; [@B23]; [@B13]; [@B31]) have only been verified with respect to the concordance of describing between-subject variability in CYP3A phenotype, in cases with sporadic sampling under baseline, inhibited or induced conditions. To date, no reduced sampling protocol has been verified with respect to performance in terms of defining changes in CYP3A phenotype due to either inhibition or induction of catalytic activity within a single cohort of individuals. Notably in this regard, the prior study of [@B9] proposed a sampling interval (2--4 h) that fails to capture the midazolam absorption and distribution phases (hence cannot account for differences in C~max~). The importance of this omission being that the time course and magnitude of CYP3A induction and mechanism-based inhibition in the liver and intestine are not equivalent ([@B8]), meaning that changes in CYP3A phenotype described by midazolam AUC cannot be robustly defined unless the sampling protocol captures both C~max~ and a sufficient window of the elimination phase. Similarly, in many cases the focus has been on minimizing the number of sample draws rather than the duration over which the samples are collected ([@B14]; [@B23]), by way of example Mueller et al. ([@B14]) demonstrated that midazolam AUC can be accurately defined using only 4 data-points, albeit over an 8-h interval. The current study sought to validate if a reduced sampling interval that retains rich sampling during the first hour (i.e. focus on shorter timeframe, not fewer samples), could be used to accurately define both between-subject variability in CYP3A phenotype as well as the magnitude of change in CYP3A activity due to either induction or mechanism-based inhibition.

Methods {#s2}
=======

Study Protocol {#s2_1}
--------------

EPOK-15 is a single-center, open-label, single-sequence metabolic phenotyping study ([@B27]; [@B20]). The study protocol was approved by the Southern Adelaide Clinical Human Research Ethics Committee (SAHREC 11.15), and written informed consent was obtained from each participant prior to study enrolment ([**Figure 1**](#f1){ref-type="fig"}). The study was conducted according to the principles stated in the Declaration of Helsinki, was compliant with CPMP/ICH/135/95 GCP standards and is registered with the Australian New Zealand Clinical Trials Registry (ACTRN 12614001289606).

![CONSORT diagram showing progression of healthy participants through the trial.](fphar-10-01120-g001){#f1}

Midazolam pharmacokinetics following the administration of a 1 mg oral midazolam dose was assessed in a cohort of healthy males (n = 30; [**Table 1**](#T1){ref-type="table"}) at baseline (Day 1), following a 7 day course of rifampin (Induction phase; Day 8) and following a 3 day course of immediate release clarithromycin (Mechanism-based inhibition phase; Day 15) with a four day washout period between the induction and mechanism-based inhibition phases. Blood samples collected prior to dosing and at 0.25, 0.5, 0.75, 1, 2, 3, 4 and 6 h post-dosing were centrifuged and plasma were stored at -80°C until analysis for the determination of midazolam concentrations. Participants self-administered rifampin (300 mg daily PO) and clarithromycin (250 mg twice daily PO) from days 1--8 and days 12--14, respectively.

###### 

Summary of study participant demographics.

                         Training cohort (n = 10)   Verification cohort (n = 20)          
  ---------------------- -------------------------- ------------------------------ ------ --------------
  *Physiology*                                                                            
  Age (years)            26.7                       21 -- 32                       25.8   21 -- 34
  Height (cm)            1.76                       1.65 -- 1.82                   1.76   1.64 -- 1.93
  Weight (kg)            72.2                       62.7 -- 84.3                   76.9   57.2 -- 108
  BMI (kg/m^2^)          23.4                       20.1 -- 26.8                   24.7   18.7 -- 30.1
  *Race*                                                                                  
  Caucasian (n)          7                          12                                    
  Asian (n)              3                          8                                     
  *CYP3A genotype*                                                                        
  *CYP3A4\*1/\*1* (n)    10                         18                                    
  *CYP3A4\*1/\*22* (n)   0                          2                                     
  *CYP3A5\*3/\*3* (n)    9                          14                                    
  *CYP3A5\*1/\**3 (n)    1                          6                                     

Physiological data are mean and range, CYP3A genotypes and race are number of patients.

Sample Preparation and Analyses {#s2_2}
-------------------------------

The sample preparation and analysis for the determination of midazolam and 1-OH midazolam concentrations has been reported previously ([@B27]). Briefly, protein from 100 μl of plasma sample was precipitated using 300 μl of methanol containing 0.1% formic acid and 7.5 ng/ml d~6~-midazolam (assay internal standard). Samples were vortexed for 3 min, then centrifuged at 16,000 g for 5 min. Analytes in a 2.5 μl aliquot of the resulting supernatant were separated from the sample matrix by ultra-performance liquid chromatography (UPLC) performed on a Waters ACQUITY™ BEH C18 column (100 mm × 2.1 mm, 1.7 μm; Waters Corp., Milford, USA) using a Waters ACQUITY™ UPLC system. Column elutant was monitored by mass spectrometry, performed on a Waters Q-ToF Premier™ quadrupole, orthogonal acceleration time-of-flight tandem mass spectrometer operating in positive electron spray ionization (ESI+) mode. Selected ion data was extracted at the analyte \[M+H\]+ precursor m/z. Resulting pseudo-MRM spectra were analyzed using Waters TargetLynx™ software. Plasma analyte concentrations were determined by comparison of normalized peak areas in participant samples to those of external calibrators. As described previously, rifampin and clarithromycin plasma concentrations were also determined pre-midazolam dosing on day 8 and day 15, respectively ([@B27]).

Data Analysis {#s2_3}
-------------

Non-compartmental methods were used to calculate the area under the midazolam plasma concentration time curve (AUC~0-t~) for PK sampling intervals of 0--1, 0--2, 0--3, 0--4, and 0--6 h post midazolam dosing on study day 1 (baseline), day 8 (following a 7-day course of rifampin), and day 15 (following a 3-day course of clarithromycin). Similarly, the pharmacokinetic parameters maximal concentration (C~max~), time to maximal concentration (T~max~), elimination half life (t~1/2~), elimination rate constant (k) and full area under the curve (AUC~0-inf~) were determined using non-compartmental methods (Microsoft Excel, PK Functions for Microsoft Excel, Department of Pharmacokinetics and Drug Metabolism, Irvine, CA, USA). AUC~0-inf~ was calculated as AUC~0-6~ plus AUC~6-inf~, where AUC~6-inf~ (the extrapolated AUC) was calculated by dividing the final measured concentration (C~last~) the elimination rate constant (k~e~) determined over the period t~max~ to 6 h. In all cases the % extrapolated (AUC~6_inf~/AUC~0-inf~) was less than 20%.

The performance of test sampling intervals (AUC~0-1~, AUC~0-2~, AUC~0-3~ and AUC~0-4~) and the 1-OH midazolam to midazolam ratio measured at 3, 4, and 6 h were evaluated with respect to agreement of the normalized reduced sampling interval AUCs (or metabolite ratios) with the midazolam AUC~0-6~. Participant AUC data grouped by study phase was randomised 1:2 into training and validation data sets. The training dataset (n = 10 participants) was used to derive linear scaling factors (Equation 1) to normalize each of the AUC~0-1~, AUC~0-2~, AUC~0-3~ and AUC~0-4~ to the AUC~0-6~.
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where "factor" is the scaling factor determined for each sampling interval ([**Table 4**](#T4){ref-type="table"}), and "t" is the final sampling time for each interval (i.e., 1, 2, 3, or 4 h).

Validation datasets (n = 60) for midazolam AUC~0-1~, AUC~0-2~, AUC~0-3~ and AUC~0-4~ were normalized to AUC~0-6~ using the scaling factor derived from the respective training sets. Bland-Altman analyses were performed to evaluate the correlation between AUC~0-6~ and the normalized reduced sampling interval AUCs calculated from reduced PK sampling intervals. Linear regression was performed to assess proportional bias based on the influence of mean AUC (normalized reduced sampling interval AUC and AUC~0-6~) on the difference in AUC (normalized reduced sampling interval AUC versus AUC~0-6~).

The performance of each reduced sampling interval AUC was also evaluated with respect to the concordance of the change (Δ) in midazolam exposures due to induction and mechanism-based inhibition of CYP3A. Using the same validation data set described for the assessment of the performance of the absolute AUC, midazolam AUC ratios were calculated for induction (AUC~day8~/AUC~day1~) and inhibition (AUC~day15~/AUC~day1~). Bland-Altman analyses were performed to evaluate the correlation between the respective AUC ratios for the reduced sampling interval AUCs and the corresponding AUC~0-6~ ratio. Linear regression was performed to assess proportional bias based on the influence of mean of the normalized reduced sampling interval AUCs and AUC~0-6~ parameters on the difference between the normalized reduced sampling interval AUCs and the AUC~0-6~ parameters. Bland-Altman plots were created by plotting the difference between the normalized reduced interval AUC and the AUC~0-6~ on the y-axis and the mean of the reduced interval AUC and the AUC~0-6~ on the y-axis.

Criteria for the acceptance of a reduced sampling interval AUC in the validation dataset were:

-   An R^2^ for the correlation of the test parameter (AUC or AUC ratio) with the AUC~0-6~ parameter of \>0.85 with and without applying a forced zero intercept.

-   A slope for the correlation of the test parameter with the AUC~0-6~ parameter in the range 0.9 to 1.1 when applying a forced zero intercept.

-   A lack of statistical significance for a one sample *t*-test of the difference in test and AUC~0-6~ parameters versus 0.

-   A lack of statistical significance for the linear regression of the effect of the mean of normalized reduced sampling interval AUC and AUC~0-6~ on the difference between the normalized reduced sampling interval AUC and the AUC~0-6~. That is to exclude a proportional bias in the dataset, and to ensure that the magnitude and direction of difference between the normalized reduced sampling interval AUC and the AUC~0-6~ is independent of the magnitude of the mean of these AUCs.

Results {#s3}
=======

Midazolam Exposure {#s3_1}
------------------

A summary of the geometric mean (95% CI) midazolam AUC baseline, post- induction and post- mechanism-based inhibition are reported in [**Table 2**](#T2){ref-type="table"}. Additional pharmacokinetic parameters defining midazolam exposure for each study phase are reported in [**Table 3**](#T3){ref-type="table"}. The distribution of midazolam concentration time profiles within the training and verification datasets for each of the three study phases (baseline, induction and mechanism based inhibition) is shown in [**Figure 2**](#f2){ref-type="fig"}. There were no statistically significant differences in parameter estimates between the full, training and validation data sets. Dosing of rifampin (300 mg daily) for 7 days resulted in mean 69% and 68% reductions in midazolam AUC~0-6~ and C~max~, respectively. Dosing of clarithromycin (250 mg twice daily) for 3 days resulted in mean 49% and 40% increases in midazolam AUC~0-6~ and C~max~, respectively.

###### 

AUC values defining midazolam exposure in the training, verification and full cohorts.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter     Study\        Training cohort (n = 10)   Verification cohort (n = 20)   Full cohort (n = 30)                                             
                phase                                                                                                                                    
  ------------- ------------- -------------------------- ------------------------------ ---------------------- ------ ------ ------------- ------ ------ ------
  AUC~0-1~\     Control       4.4                        2.4                            6.3                    4      3      4.9           4.1    3.3    4.9
  (ng/ml/h)                                                                                                                                              

  Induced       2 (0.45)      0.6                        3.5                            1.2 (0.30)             0.9    1.5    1.5 (0.37)    1.0    2.0    

  Inhibited     6.4 (1.45)    3.7                        9                              5.8 (1.45)             4.1    7.6    5.9 (1.44)    4.6    7.2    

  AUC~0-2~\     Control       9                          5.6                            12.4                   8.4    6.6    10.3          8.6    7.1    10.2
  (ng/ml/h)                                                                                                                                              

  Induced       3.4 (0.38)    1                          5.9                            2.1 (0.25)             1.6    2.6    2.6 (0.30)    1.7    3.4    

  Inhibited     14 (1.56)     9.1                        19                             12.3 (1.46)            9      15.7   12.6 (1.47)   10.1   15.2   

  AUC~0-3~\     Control       12.3                       7.7                            16.8                   11.4   9      13.9          11.7   9.6    13.8
  (ng/ml/h)                                                                                                                                              

  Induced       4.6 (0.37)    1.2                        8.1                            2.8 (0.25)             2.1    3.4    3.4 (0.29)    2.2    4.5    

  Inhibited     19.3 (1.57)   13                         25.6                           16.8 (1.47)            12.2   21.5   17.3 (1.48)   13.8   20.8   

  AUC~0-4~\     Control       14.7                       9.1                            20.3                   13.5   10.6   16.4          13.9   11.4   16.4
  (ng/ml/h)                                                                                                                                              

  Induced       5.7 (0.39)    1.4                        10                             3.3 (0.24)             2.5    4.2    4.1 (0.31)    2.7    5.5    

  Inhibited     22.7 (1.54)   15.8                       29.5                           20.0 (1.48)            14.4   25.7   20.5 (1.49)   16.3   24.6   

  AUC~0-6~\     Control       18.3                       10.8                           25.9                   16.2   12.7   19.7          16.9   13.8   20.1
  (ng/ml/h)                                                                                                                                              

  Induced       7.2 (0.39)    1.5                        12.9                           4.4 (0.27)             3.1    5.7    5.3 (0.31)    3.4    7.2    

  Inhibited     28.2 (1.54)   20.1                       36.3                           24.6 (1.52)            17.7   31.5   25.2 (1.49)   20.2   30.3   

  AUC~0-inf~\   Control       24.8                       11.8                           37.8                   20.2   15.7   24.6          21.6   16.7   26.4
  (ng/ml/h)                                                                                                                                              

  Induced       13.4 (0.54)   1.8                        28.6                           7.6 (0.38)             4.1    11.1   9.6 (0.44)    4.5    14.6   

  Inhibited     50.6 (2.04)   22.3                       78.9                           31.6 (1.56)            22.7   40.5   38.1 (1.76)   27.5   48.7   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Ratio of induced (post- rifampin)/control parameter for 'Induced' and inhibited (post- clarithromycin)/control parameter for 'inhibited' study phases.

###### 

Pharmacokinetic parameters defining midazolam concentration time profile in the training, verification and full cohorts.

  ------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter   Study\    Training cohort (n = 10)   Verification cohort (n = 20)   Full cohort (n = 30)                                      
              phase                                                                                                                         
  ----------- --------- -------------------------- ------------------------------ ---------------------- ------ ------ ------ ------ ------ ------
  C~max~\     Control   7                          4.5                            9.5                    6.3    4.7    7.8    6.5    5.3    7.7
  (ng/ml)                                                                                                                                   

  Induced     2.8       0.8                        4.9                            1.7                    1.2    2.2    2.1    1.4    2.8    

  Inhibited   9.5       6                          13                             8.9                    6.4    11.4   9.1    7.2    11.0   

  T~max~\     Control   0.83                       0.47                           1.18                   0.83   0.62   1.03   0.83   0.66   1.00
  (h)                                                                                                                                       

  Induced     0.55      0.33                       0.77                           0.65                   0.46   0.85   0.62   0.47   0.76   

  Inhibited   0.75      0.58                       0.92                           0.98                   0.75   1.20   0.90   0.74   1.06   

  T~1/2~\     Control   2.4                        1.6                            3.1                    2.2    1.8    2.5    2.2    1.9    2.5
  (h)                                                                                                                                       

  Induced     1.5       1.0                        2.5                            1.5                    1.2    2.8    1.3    0.9    2.2    

  Inhibited   2.7       1.6                        3.7                            2.7                    2.2    3.2    2.5    2.1    2.9    

  CL/F\       Control   55.7                       36.6                           74.8                   62.1   47.2   77.1   60.0   48.8   71.2
  (L/h)                                                                                                                                     

  Induced     276       136                        417                            239                    176    302    251    193    309    

  Inhibited   28.6      18.3                       38.9                           42.9                   31.2   54.7   38.1   29.6   46.6   
  ------------------------------------------------------------------------------------------------------------------------------------------------

![Midazolam plasma concentration time plots for baseline **(A)**, induction **(B)** and Mechanism-based inhibition **(C)** study phases. Triangles represent training dataset, circles represent verification dataset, dashed line represents mean profile for the full dataset.](fphar-10-01120-g002){#f2}

Capacity of Reduced Sampling Interval to Define Absolute Midazolam AUC {#s3_2}
----------------------------------------------------------------------

A training dataset (n = 10; 30 data points) was used to derive equations that normalized each reduced sampling interval AUC (AUC~0-1~, AUC~0-2~, AUC~0-3~, and AUC~0-4~) to midazolam AUC~0-6~ ([**Table 4**](#T4){ref-type="table"}). The concordance of each normalized reduced interval AUC with the AUC~0-6~ is visualized as correlation and Bland-Altman plots ([**Figure 3**](#f3){ref-type="fig"}). With the exception of AUC~0-1~, the R^2^ for the correlation of each normalized reduced interval AUC with the AUC~0-6~ was \>0.85. One-sample *t*-tests demonstrated that in all cases the difference between the normalized reduced interval AUC and AUC~0-6~ were not significantly different from 0 (p ≥ 0.76). Linear regression analysis demonstrated that there was no effect of the mean midazolam AUC on the difference in midazolam AUC, indicating a lack of proportional bias within each dataset (p ≥ 0.621). Based on fulfilment of the criteria for acceptance of precision and accuracy, the shortest acceptable sampling interval for assessment of absolute midazolam AUC was 0 to 3 hours. For absolute AUC, precision was also assessed at each data point in the validation dataset (n = 20; 60 data points) as the difference between the normalized reduced interval AUC and the corresponding AUC~0-6~. In all cases the difference between the normalized reduced interval AUC estimates in the AUC~0-3~ and AUC~0-4~ datasets were \<20% of the corresponding mean parameter estimate. Similarly, analysis of the correlation of the raw midazolam AUC measured over 0 to 3, 0 to 4, and 0 to 6 h versus the full midazolam AUC (AUC~0-inf~) demonstrated that in all cases the R^2^ for the correlation was greater than 0.875 ([**Figure 4**](#f4){ref-type="fig"}).

###### 

Equations relating reduced sampling duration AUCs to AUC~0-6~ in the training, verification and full (pooled) datasets.

  Dataset                 Equation                            
  ----------------------- ----------- ----------- ----------- -----------
  Training (n = 30)       y = 3.95x   y = 1.98x   y = 1.47x   y = 1.25x
  Verification (n = 60)   Y = 3.96x   Y = 1.97x   Y = 1.45x   Y = 1.22x
  Full (n = 90)           y = 3.95x   y = 1.97x   y = 1.46x   y = 1.23x

![Concordance of midazolam exposure between normalized reduced sampling interval AUCs and AUC~0-6~ in the validation cohort. **(A**, **C**, **E**, and **G)** Correlation plots for the AUC~0-1~, AUC~0-2~, AUC~0-3~ and AUC~0-4~ sampling intervals respectively. **(B**, **D**, **F**, and **H)** Bland-Altman plots (mean of normalized reduced sampling interval AUCs and AUC~0-6~ parameters versus difference between normalized reduced sampling interval AUCs and AUC~0-6~ parameters) for the AUC~0-1~, AUC~0-2~, AUC~0-3~, and AUC~0-4~ sampling intervals, respectively. Lines describe the mean difference (blue line), 95% confidence interval around the mean difference (green lines) and the zero difference reference (orange line). Units: AUC; ng/mL/h.](fphar-10-01120-g003){#f3}

![Concordance of midazolam exposure between AUC~0-3~, AUC~0-4~, and AUC~0-6~ and the full AUC (AUC~0-inf~) in the validation cohort. **(A**, **B**, **C)** Correlation plots for the AUC~0-3~, AUC~0-4~, and AUC~0-6~ sampling intervals, respectively. Units: AUC; ng/mL/h.](fphar-10-01120-g004){#f4}

Capacity of Reduced Sampling Interval to Define Change in Midazolam AUC Due to Induction {#s3_3}
----------------------------------------------------------------------------------------

Correlation of the AUC~0-3~ (R^2^ = 0.94) and AUC~0-4~ (R^2^ = 0.98) ratios with the AUC~0-6~ ratio fulfilled the criteria of an R^2^ \> 0.85, whereas the R^2^ for the correlation of the AUC~0-1~ and AUC~0-2~ ratios with the AUC~0-6~ ratio failed to meet this criteria. One-sample *t*-tests demonstrated that in all cases the difference between the reduced interval AUC ratios and the AUC~0-6~ ratio were not significantly different from 0 (p ≥ 0.062). Linear regression analysis demonstrated that there was no effect of the mean AUC ratio on the difference in the AUC ratio, indicating a lack of proportional bias within each dataset (p ≥ 0.065). Based on fulfilment of the criteria for acceptance of precision and accuracy, the shortest acceptable sampling interval for assessment of induction of midazolam AUC was 0 to 3 h. The correlation of the Day 8/Day 1 (induction) AUC ratio for the AUC~0-3~ reduced sampling interval compared to the AUC~0-6~ ratio is presented in [**Figure 5A**](#f5){ref-type="fig"}. Bland-Altman plots for each reduced sampling interval AUC are presented in [**Supplemental Figure 1**](#SM1){ref-type="supplementary-material"}.

![Correlation plots demonstrating the concordance of the change in midazolam AUC due to induction **(A)** and mechanism-based inhibition **(B)** between the normalized 0 to 3 h reduced sampling interval AUC (AUC~0-3~) and AUC~0-6~ in the verification cohort.](fphar-10-01120-g005){#f5}

Capacity of Reduced Sampling Interval to Define Change in Midazolam AUC Due to Inhibition {#s3_4}
-----------------------------------------------------------------------------------------

Correlation of the AUC~0-3~ (R^2^ = 0.87) and AUC~0-4~ (R^2^ = 0.97) ratios with the AUC~0-6~ ratio fulfilled the criteria of an R^2^ \> 0.85, whereas the R^2^ for the correlation of the AUC~0-1~ and AUC~0-2~ ratios with the AUC~0-6~ ratio failed to meet this criteria. One-sample *t*-tests demonstrated that in all cases the difference between the reduced interval AUC ratios and AUC~0-6~ ratio were not significantly different from 0 (p ≥ 0.148). Linear regression analysis demonstrated that there was no effect of the mean midazolam AUC ratio on the difference in midazolam AUC ratio, indicating a lack of proportional bias within each dataset (p ≥ 0.277). Based on fulfilment of the criteria for acceptance of precision and accuracy, the shortest acceptable sampling interval for assessment of induction of midazolam AUC was 0 to 3 h. The correlation of the Day 15/Day 1 (mechanism-based inhibition) AUC ratio for the AUC~0-3~ reduced sampling interval compared to the AUC~0-6~ ratio is presented in [**Figure 5B**](#f5){ref-type="fig"}. Bland-Altman plots for each reduced sampling interval AUC are presented in [**Supplemental Figure 2**](#SM1){ref-type="supplementary-material"}.

Comparison of Midazolam AUC~0-3~ With Reported Alternate Metrics {#s3_5}
----------------------------------------------------------------

Results described above evaluate the absolute performance of the midazolam AUC~0-3~ with respect to defining midazolam exposure. The capacity of midazolam AUC~0-3~ to define midazolam exposure was also evaluated with respect to comparative performance by reproducing previously proposed metrics in the current validation dataset.

Consistent with the prior analysis of [@B3], the correlation of single time point midazolam concentrations at 3, 4, and 6 h with midazolam AUC~0-6~ varied between time point and study phases; R^2^ values ranged from 0.357 (6 h control phase) and 0.917 (3 h inhibition phase) ([**Supplemental Figures 3A--C**](#SM1){ref-type="supplementary-material"}). Correlations of single time point measures with AUC~0-6~ were consistently strongest at the 3 h time point (R^2^ 0.809, 0.879, and 0.917 for baseline, induced, and inhibited phases, respectively), and for the inhibition study phase (R^2^ 0.917, 0.888, and 0.742 for 3, 4, and 6 h time points, respectively). In comparison, the R^2^ vales for the correlation of midazolam AUC~0-3~ with AUC~0-6~ for the control, induction, and inhibition study phases were 0.931, 0.906, and 0.971, respectively ([**Supplemental Figure 3D**](#SM1){ref-type="supplementary-material"}).

Similarly, consistent with the conclusion of [@B11], correlation of single time point OH-midazolam to midazolam ratios at 3, 4, and 6 h with AUC~0-6~ consistently yielded R^2^ values \<0.8 for both individual study phases and pooled study phases (not shown).

Discussion {#s4}
==========

Here we describe, for the first time, the validation of a 3-h midazolam sampling interval to support the assessment of between-subject variability in CYP3A phenotype across specific sub-populations as well as the evaluation of changes in CYP3A function due to induction and mechanism-based inhibition of this enzyme. The key distinctions between the current analysis and prior analyses ([@B11]; [@B9]; [@B14]; [@B23]; [@B13]; [@B31]) are a) the current study design has allowed for not only the validation of performance under normal, induced and inhibited conditions, but critically also the validation of performance with respect to describing the change in CYP3A function caused by induction and inhibition, and b) the primary focus of the current analysis was to reduce the duration over which samples are collected (i.e. retained rich sampling in the first 2 h), whereas prior analyses have focused on minimizing the number of sample collections (i.e., fewer samples, but at times over a longer period up to 8 h). The robustness of the approach is supported by post-hoc analysis demonstrating that the scaling factor used to normalize the reduced interval AUCs in the training dataset were independently reproducible in the verification and full datasets. Based on these data, a reproducible scaling factor of 1.46 (full dataset value) is proposed to facilitate future normalizations of AUC~0-3~ data to prior or alternate studies where AUC~0-6~ has been measured.

In this regard, prior pooled analyses of three ([@B10]) and seven ([@B13]) trials did evaluate the performance of reduced sampling interval AUCs under normal, induced and inhibited conditions, however, data for each set of conditions came from different study cohorts. Critically the use of different cohorts for each set of conditions precluded these prior studies from evaluating performance with respect to the change in CYP3A function caused by induction or inhibition. Similarly, the prior study of [@B9] only considered the performance of reduced sampling interval AUCs under normal conditions. Indeed, the sampling interval proposed by [@B9] explicitly prevents interpretation of the changes midazolam bioavailability (which are predominantly observed as changes in the maximal plasma concentration; C~max~), which, given the low midazolam basal f~g~ of 0.26, is a major factor driving the reduction in midazolam AUC associated with induction of CYP3A ([@B8]). Furthermore, it is worth noting that while the current study validated a longer reduced PK sampling interval compared to [@B9] (3 h versus 2 h), the actual time commitment for study participants and staff following midazolam dosing proposed in the current study is 1 h shorter (3 h versus 4 h) as the sampling interval of Katzenmaier et al. has a 2-h lag phase between midazolam dosing and sample collection. Similarly, consistent with the findings of [@B11] and [@B3], AUC~0-3~ outperformed both single time point midazolam and single time point OH-midazolam to midazolam ratios with respect to defining variability in midazolam AUC~0-6~.

Caution is recommended when extrapolating AUC~0-inf~ based on a measured AUC defining \<80% due to a risk of bias and variance associated with the estimation of the elimination rate constant ([@B15]). In the cohort analyzed here (n = 30; 90 data points), extrapolation of the midazolam AUC measured over six hours (AUC~0-6~) to infinity accounted for 82%, 83%, and 80% of the AUC~0-inf~ for the baseline, induced, and inhibited study phases, respectively. By comparison, extrapolation of the AUC~0-4~ accounted for only 66%, 68%, and 64% of the AUC~0-inf~ for the baseline, induced, and inhibited phases, respectively. This limitation is important to consider when determination of midazolam apparent oral clearance (CL/F) is the primary variable being considered, as calculation of CL/F requires robust determination of AUC~0-inf~. Under such circumstances the use of a reduced sampling interval AUC may not be appropriate as this strategy does not meet the criteria for extrapolation of AUC~0-inf~. It is worth noting however, that data presented in [**Figure 4**](#f4){ref-type="fig"} support the capacity of reduced sampling intervals measured over 0 to 3 and 0 to 4 h to define \>87% of the variability in AUC~0-inf~. Two further limitations that are specific to the current analysis were 1) that while the cohort contained individuals of an appropriate age range for healthy volunteer studies (i.e., 21 to 35 years), the cohort was exclusively male, and 2) the full AUC (AUC~0-inf~) was estimated by extrapolation of the AUC~0-6~ data. However, 1) there is no reason to suspect a gender difference in the performance of a reduced sampling interval AUC given that there is not a statistically significant gender difference observed for the change in midazolam AUC~0-6~ due to induction of CYP3A4 ([@B8]). Similarly, 2) the AUC~0-6~ data accounted for \>80% of the full AUC, and thus is likely to provide a robust estimation of this parameter, although full validation of this approach metric should be undertaken in either a prospective study, or by reanalysis of an existing dataset where AUC~0-24~ has been captured.

The reduction in logistical burden associated with reducing the sampling interval for midazolam-based CYP3A phenotyping is likely to have the greatest impact for research performed in academia and clinical sites. Typically, in the pharmaceutical industry, drug-drug interaction (DDI) studies with midazolam are typically designed to assess drug concentration out to 24--48 h to calculate AUC over this PK sampling interval as well as AUC~inf~. Depending on the mechanism of the DDI (inhibition vs induction) and magnitude (none-weak-moderate-strong), such protocols make use of all available data points to calculate midazolam AUC (within assay limits). There may however be industry applications to a reduced sampling interval AUC for midazolam-based CYP3A phenotyping, in terms of reducing blood draws when phenotyping pediatrics, elderly or other vulnerable populations.

A number of recent studies have attempted to remove the requirement to dose a drug probe to assess CYP3A phenotype by measuring either an endogenous small molecule substrate for this enzyme ([@B28]; [@B4]; [@B1]; [@B12]), or endogenous protein/nucleic acid biomarker for this enzyme ([@B16]). While endogenous exosome derived biomarkers ([@B20]) appear to represent a promising avenue moving forward, the robust validation of such strategies in both healthy volunteer and patient cohorts require substantial work, thus clinical phenotyping for CYP3A, based on midazolam PK assessment, will likely remain an important tool in both academic and industry research settings for many years.

In conclusion, the current study demonstrates a robust concordance between midazolam AUC calculated by either 0 to 3 and 0 to 6 h PK sampling intervals in terms of both the measurement of between subject variability and changes in midazolam exposure due to induction and mechanism-based inhibition of CYP3A4. On this basis, it is proposed that assessment of a 0 to 3hr midazolam AUC (AUC~0-3~) represents a viable strategy to reduce the logistical burden associated with the assessment of CYP3A phenotype and perturbations of phenotype caused by CYP3A induction or mechanism-based inhibition.
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